TEZSPIRE meets both co-primary endpoints in Phase 3 eosinophilic esophagitis trial

Amgen and AstraZeneca reported positive topline results from the Phase 3 CROSSING trial of TEZSPIRE in eosinophilic esophagitis on August 27, 2026. The drug beat placebo on both co-primary endpoints, histologic remission and dysphagia frequency and severity, at week 24, and the benefit held through week 52. The release gave no effect sizes or p-values, so the size of the effect is not yet public.

• 368 patients randomized 1:1:1 to a low dose, a high dose or placebo
• Co-primary endpoints at week 24: histologic remission and dysphagia (DSQ)
• Benefit sustained through week 52
• Safety generally consistent with TEZSPIRE's approved indications
• Full data to regulators and an upcoming medical meeting; no date given